Tag: biologics

The global birch allergy market is experiencing robust growth due to increasing cases of allergic rhinitis from birch pollen and advancements in treatments like immunotherapy. Rising awareness and improved healthcare infrastructures in key regions such as the U.S., U.K., and Germany drive market expansion. Key therapies, including antihistamines and sublingual immunotherapy, are evolving alongside biologics and targeted treatments for severe cases. Despite challenges like high costs and regulatory hurdles, strategic partnerships and R&D in biologics are shaping the market. Ongoing innovations and digital health integrations are set to enhance patient outcomes globally.

Louvain-la-Neuve, Belgium, June 18, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, announced today it has signed a contract with Steri-Tek, a growing irradiation services provider, to install a fully-integrated Be Wide X-ray Solution.

Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases.

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.